ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease
December 01, 2022 20:26 ET
|
Anavex Life Sciences Corp.
Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADLKey Secondary Endpoint CDR-SB Also Met, Demonstrating...
Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
November 28, 2022 07:00 ET
|
Anavex Life Sciences Corp.
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022
November 23, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference 2022
November 08, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome
November 07, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022
October 17, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy
September 21, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease
August 23, 2022 07:00 ET
|
Anavex Life Sciences Corp.
Mechanism of Action of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) is the activation of SIGMAR1 Endogenous increase in SIGMAR1 activation as a compensatory mechanism against early Alzheimer's...
Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Third Quarter Financial Results
August 09, 2022 07:00 ET
|
Anavex Life Sciences Corp.
Company to host a webcast today at 4:30 p.m. Eastern Time NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday August 9, 2022
August 03, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...